Terms: = Lymphoma AND ALK, CD246, ENSG00000171094, 238, Q9UM73, TFG/ALK AND Clinical Outcome
91 results:
1. clinical outcomes of
Hansen KH; Johansen JS; Urbanska EM; Meldgaard P; Hjorth-Hansen P; Kristiansen C; Stelmach M; Santoni-Rugiu E; Ulhøi MP; Dydensborg AB; Dünweber C; Andersen JL
Acta Oncol; 2023 Dec; 62(12):1775-1783. PubMed ID: 37815923
[TBL] [Abstract] [Full Text] [Related]
2.
Qiu L; Tang G; Li S; Vega F; Lin P; Wang SA; Wang W; Iyer SP; Malpica L; Miranda RN; Konoplev S; Tang Z; Fang H; Medeiros LJ; Xu J
Haematologica; 2023 Jun; 108(6):1604-1615. PubMed ID: 36453104
[TBL] [Abstract] [Full Text] [Related]
3. Concurrent classic driver oncogenes mutation with ROS1 rearrangement predicts superior clinical outcome in NSCLC patients.
Li D; Jiang H; Jin F; Pan L; Xie Y; Zhang L; Li C
Genes Genomics; 2023 Jan; 45(1):93-102. PubMed ID: 36445572
[TBL] [Abstract] [Full Text] [Related]
4. Detection of alk fusion variants by RNA-based NGS and clinical outcome correlation in NSCLC patients treated with alk-TKI sequences.
Tabbò F; Muscarella LA; Gobbini E; Trombetta D; Castellana S; Rigutto A; Galetta D; Maiello E; Martelli O; Tiseo M; Scotti V; Ghilardi L; Gregorc V; Sergi C; Pilotto S; Del Conte A; Cappuzzo F; Cortinovis D; Osman G; Bareggi C; Di Maio M; Rossi A; Rossi G; Bria E; Volante M; Scagliotti GV; Graziano P; Novello S; Righi L
Eur J Cancer; 2022 Oct; 174():200-211. PubMed ID: 36044814
[TBL] [Abstract] [Full Text] [Related]
5. Systemic alk-negative anaplastic large cell lymphoma with distinctive myxoid change and DUSP22 rearrangement.
Fratoni S; Trawinska MM; Capalbo A; Bernardini L; Fabbretti M; Martini M; Niscola P; Zhao XF
Virchows Arch; 2022 Dec; 481(6):975-979. PubMed ID: 35879438
[TBL] [Abstract] [Full Text] [Related]
6. Long-term remission of primary refractory alk-positive anaplastic large cell lymphoma after allogeneic hematopoietic stem cell transplantation.
Miyazaki M; Ichikawa S; Onishi Y; Fukuhara N; Furukawa E; Onodera K; Yokoyama H; Ichinohasama R; Harigae H
J Clin Exp Hematop; 2022 Sep; 62(3):164-168. PubMed ID: 35732409
[TBL] [Abstract] [Full Text] [Related]
7. Characterizing kinase intergenic-breakpoint rearrangements in a large-scale lung cancer population and real-world clinical outcomes.
Yao Y; Yu Z; Ma Y; Ou Q; Wu X; Lu D; Li X
ESMO Open; 2022 Apr; 7(2):100405. PubMed ID: 35305401
[TBL] [Abstract] [Full Text] [Related]
8. Genetic landscape of patients with alk-rearranged non-small-cell lung cancer (NSCLC) and response to ceritinib in ASCEND-1 study.
Tan DS; Thomas M; Kim DW; Szpakowski S; Urban P; Mehra R; Chow LQM; Sharma S; Solomon BJ; Felip E; Camidge DR; Vansteenkiste J; Petruzzelli L; Pantano S; Shaw AT
Lung Cancer; 2022 Jan; 163():7-13. PubMed ID: 34890832
[TBL] [Abstract] [Full Text] [Related]
9. Combined Detection of Copy Number Variations of MYCN and alk using Droplet Digital Polymerase Chain Reaction to Identify High-Risk Patients with Neuroblastoma.
Trivedi T; Panchal K; Bhalala N; Trivedi P; Panchal H
World Neurosurg; 2022 Mar; 159():e48-e57. PubMed ID: 34861448
[TBL] [Abstract] [Full Text] [Related]
10. clinical outcome, long-term survival and tolerability of sequential therapy of first-line crizotinib followed by alectinib in advanced alk+NSCLC: A multicenter retrospective analysis in China.
Zou Z; Hao X; Zhang C; Li H; Dong G; Peng Y; Ma K; Guo Y; Shan L; Zhang Y; Liang L; Gu Y; Xing P; Li J
Thorac Cancer; 2022 Jan; 13(1):107-116. PubMed ID: 34851035
[TBL] [Abstract] [Full Text] [Related]
11. Association of anaplastic lymphoma kinase variants and alterations with ensartinib response duration in non-small cell lung cancer.
Hou D; Zheng X; Song W; Liu X; Wang S; Zhou L; Tao X; Lv L; Sun Q; Jin Y; Zhang Z; Ding L; Wu N; Zhao S
Thorac Cancer; 2021 Sep; 12(17):2388-2399. PubMed ID: 34288491
[TBL] [Abstract] [Full Text] [Related]
12. Brigatinib versus other second-generation alk inhibitors as initial treatment of anaplastic lymphoma kinase positive non-small cell lung cancer with deep phenotyping: study protocol of the ABP trial.
Christopoulos P; Bozorgmehr F; Brückner L; Chung I; Krisam J; Schneider MA; Stenzinger A; Eickhoff R; Mueller DW; Thomas M
BMC Cancer; 2021 Jun; 21(1):743. PubMed ID: 34182952
[TBL] [Abstract] [Full Text] [Related]
13. Anaplastic lymphoma kinase tyrosine kinase inhibitor-induced hepatic failure in lung cancer patients: A study of signal mining and analysis of the FDA adverse event reporting system database.
Zhou Z; Wang C; Ying L; Jin M; Zhang F; Shi D
J Clin Pharm Ther; 2021 Aug; 46(4):1148-1154. PubMed ID: 33768534
[TBL] [Abstract] [Full Text] [Related]
14. Distribution and therapeutic outcomes of intergenic sequence-alk fusion and coexisting alk fusions in lung adenocarcinoma patients.
Cai C; Tang Y; Li Y; Chen Y; Tian P; Wang Y; Gong Y; Peng F; Zhang Y; Yu M; Wang K; Zhu J; Lu Y; Huang M
Lung Cancer; 2021 Feb; 152():104-108. PubMed ID: 33444901
[TBL] [Abstract] [Full Text] [Related]
15. Crizotinib versus chemotherapy: a real-world cost-effectiveness study in China.
Huang M; Tian Y; He M; Liu J; Ren L; Gong Y; Peng F; Wang Y; Ding Z; Wang J; Zhu J; Xu Y; Liu Y; Li L; Lu Y
J Comp Eff Res; 2020 Jan; 9(2):93-102. PubMed ID: 31958984
[No Abstract] [Full Text] [Related]
16. Targetable molecular alterations in congenital glioblastoma.
Gilani A; Donson A; Davies KD; Whiteway SL; Lake J; DeSisto J; Hoffman L; Foreman NK; Kleinschmidt-DeMasters BK; Green AL
J Neurooncol; 2020 Jan; 146(2):247-252. PubMed ID: 31875306
[TBL] [Abstract] [Full Text] [Related]
17. Ukraine Data on Prognostic Factors and Treatment outcomes in Patients with Peripheral T-Cell lymphomas.
Skrypets T; Novosad O; Pastushenko Y; Gorbach O; Kriachok I
Klin Onkol; 2019; 32(6):436-444. PubMed ID: 31842562
[TBL] [Abstract] [Full Text] [Related]
18. NK cell-based therapeutics for lung cancer.
Pockley AG; Vaupel P; Multhoff G
Expert Opin Biol Ther; 2020 Jan; 20(1):23-33. PubMed ID: 31714156
[No Abstract] [Full Text] [Related]
19. Analysis of the Genomic Landscape in alk+ NSCLC Patients Identifies Novel Aberrations Associated with clinical outcomes.
Couëtoux du Tertre M; Marques M; Tremblay L; Bouchard N; Diaconescu R; Blais N; Couture C; Pelsser V; Wang H; Higenell V; Izzi L; Gambaro K; Hoffert C; Srivastava A; Spatz A; Rousseau C; McNamara S; Cohen V; Batist G; Agulnik J
Mol Cancer Ther; 2019 Sep; 18(9):1628-1636. PubMed ID: 31243098
[TBL] [Abstract] [Full Text] [Related]
20. Treatment of oncogene-driven non-small cell lung cancer.
Kastelijn EA; de Langen AJ; Peters BJM
Curr Opin Pulm Med; 2019 May; 25(3):300-307. PubMed ID: 30865033
[TBL] [Abstract] [Full Text] [Related]
[Next]
